iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
(new Study) Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-9857 (pan-genotypic protease) in Subjects With Chronic Hepatitis C Virus Infection
 
 
  .....https://clinicaltrials.gov/ct2/show/NCT02185794
 
This study will evaluate the safety, tolerability, and antiviral activity of GS-9857 in adults with genotypes 1, 2, 3, or 4 hepatitis C virus (HCV) infection. GS-9857 will be administered daily for 3 consecutive days. All participants will be monitored for up to 48 weeks after last dose to monitor for persistence of viral mutations.

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org